-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ABrD42qSozEYS3+gOFg4uT4zj48v4Cl9QFukDN4s10V2qpDqtuENGGfHlwP0oGTo ywiWYQPyAbfBu9Pr8QezdQ== 0000905148-03-000617.txt : 20030214 0000905148-03-000617.hdr.sgml : 20030214 20030214170941 ACCESSION NUMBER: 0000905148-03-000617 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030214 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: INTERNATIONAL BM BIOMEDICINE HOLDINGS INC CENTRAL INDEX KEY: 0001134905 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: NAUENSTRASSO 41 POSTFACH BASEL STREET 2: SWITZERLAND CH 4002 MAIL ADDRESS: STREET 1: NAUENSTRASSO 41 POSTFACH BASEL STREET 2: SWITZERLAND CH 4002 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ALLOS THERAPEUTICS INC CENTRAL INDEX KEY: 0001097264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 541655029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-60251 FILM NUMBER: 03568396 BUSINESS ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 200 CITY: WESTMINSTER STATE: CO ZIP: 80020 BUSINESS PHONE: 3034266262 MAIL ADDRESS: STREET 1: 7000 NORTH BROADWAY STREET 2: SUITE 400 CITY: DENVER STATE: CO ZIP: 80221 SC 13G 1 efc3-0263_sch13g.txt GLOBAL BIOMEDICAL PARTNERS-ALLOS THERAPEUTICS OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response... 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Allos Therapeutics, Inc. - ------------------------------------------------------------------------------ (Name of Issuer) Common Stock - ------------------------------------------------------------------------------ (Title of Class of Securities) 019777101 - ------------------------------------------------------------------------------ (CUSIP Number) December 31, 2002 - ------------------------------------------------------------------------------ (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (02-02) Page 1 of 6 CUSIP No. 019777101 - ------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). International BM Biomedicine Holdings AG - ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) - ------------------------------------------------------------------------------ 3. SEC Use Only - ------------------------------------------------------------------------------ 4. Citizenship or Place of Organization Basel, Switzerland. - ------------------------------------------------------------------------------ 5. Sole Voting Power 778,707 ----------------------------------------------------------- 6. Shared Voting Power ----------------------------------------------------------- 7. Sole Dispositive Power 778,707 ----------------------------------------------------------- 8. Shared Dispositive Power - ------------------------------------------------------------------------------ 9. Aggregate Amount Beneficially Owned by Each Reporting Person. 778,707 - ------------------------------------------------------------------------------ 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions). - ------------------------------------------------------------------------------ 11. Percent of Class Represented by Amount in Row (9) 3.0% - ------------------------------------------------------------------------------ 12. Type of Reporting Person (See Instructions) CO Page 2 of 6 Item 1. (a) Name of Issuer Allos Therapeutics, Inc. (b) Address of Issuer's Principal Executive Offices: 7000 North Broadway, Suite 400, Denver, CO 80221 Item 2. (a) Name of Person Filing International BM Biomedicine Holdings AG (b) Address of Principal Business Office or, if none, Residence Nauenstrasse 41, P.O.Box 4002, Basel, Switzerland (c) Citizenship Switzerland (d) Title of Class of Securities Common Stock (e) CUSIP Number 019777101 Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) [ ] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with ss. 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J). Page 3 of 6 Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 778,707 (b) Percent of class: 3.0% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 778,707 (ii) Shared power to vote or to direct the vote (iii) Sole power to dispose or to direct the disposition of 778,707. (iv) Shared power to dispose or to direct the disposition of Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not Applicable Page 4 of 6 Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. 778,707 of the shares beneficially owned by the Reporting Person reported herein are owned directly by Biomedicine LP. The general partner of Biomedicine LP is International BM Biomedicine Holdings (Cayman) Ltd., which is wholly owned by the Reporting Person. Item 8. Identification and Classification of Members of the Group Not Applicable Item 9. Notice of Dissolution of Group Not Applicable Page 5 of 6 Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 14, 2003 ----------------- Date INTERNATIONAL BM BIOMEDICINE HOLDINGS AG Dr. Gaudenz I. Staehelin / Vice-Chairman ---------------------------------------- Name/Title Patrick Weber / CEO ------------------- Name/Title Page 6 of 6 -----END PRIVACY-ENHANCED MESSAGE-----